Status:

ENROLLING_BY_INVITATION

Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures

Lead Sponsor:

University of California, Irvine

Conditions:

Rib Fractures

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Rib fractures cause a significant amount of pain and are associated with an increased risk of lung infections, long hospitalization, and increased cost. Effective pain control is the cornerstone of ma...

Detailed Description

Rib fractures are a common and painful injury associated with increased risk of pneumonia, prolonged hospitalization, and higher healthcare utilization. In a national database review, rib fractures we...

Eligibility Criteria

Inclusion

  • \> 18 years old
  • Blunt trauma patients
  • \> 3 rib fractures
  • Able to tolerate oral intake

Exclusion

  • \< 17 years old
  • Pregnant
  • Prisoners
  • History of adverse reaction to suzetrigine
  • Current strong CYP3A inhibitor medication use
  • o Strong Inhibitors: clarithromycin, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, atazanavir, darunavir, indinavir, lopinavir, telithromycin
  • Current strong or moderate CYP3A inducer
  • Strong Inducers: apalutamide, carbamazepine, encorafenib, enzalutamide, fosphenytoin, lumacaftor and ivacaftor, mitotane, phenytoin, rifampin
  • Moderate Inducers: bexarotene (Systemic), bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, estradiol, and norethindrone, eslicarbazepine, etravirine, fexinidazole, lorlatinib, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, phenobarbital, primidone, repotrectinib, rifabutin, rifapentine, sotorasib, St John's Wort
  • Cirrhosis
  • GCS \< 14
  • Rhabdomyolysis (CPK \> 5,000 U/L)
  • Chronic opioid use (\>30mg OME/day)
  • Known or suspected active infection with human immunodeficiency virus or hepatitis B or C viruses

Key Trial Info

Start Date :

November 13 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2027

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT07145346

Start Date

November 13 2025

End Date

August 1 2027

Last Update

December 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California, Irvine

Orange, California, United States, 92868